Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
- 21 July 2010
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (32), 14093-14098
- https://doi.org/10.1073/pnas.1002713107
Abstract
The pharmacologic utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability. For example, enfuvirtide (Fuzeon, T20, DP178), a 36-amino acid peptide that inhibits human immunodeficiency virus type 1 (HIV-1) infection by effectively targeting the viral fusion apparatus, has been relegated to a salvage treatment option mostly due to poor in vivo stability and lack of oral bioavailability. To overcome the proteolytic shortcomings of long peptides as therapeutics, we examined the biophysical, biological, and pharmacologic impact of inserting all-hydrocarbon staples into an HIV-1 fusion inhibitor. We find that peptide double-stapling confers striking protease resistance that translates into markedly improved pharmacokinetic properties, including oral absorption. We determined that the hydrocarbon staples create a proteolytic shield by combining reinforcement of overall alpha-helical structure, which slows the kinetics of proteolysis, with complete blockade of peptide cleavage at constrained sites in the immediate vicinity of the staple. Importantly, double-stapling also optimizes the antiviral activity of HIV-1 fusion peptides and the antiproteolytic feature extends to other therapeutic peptide templates, such as the diabetes drug exenatide (Byetta). Thus, hydrocarbon double-stapling may unlock the therapeutic potential of natural bioactive polypeptides by transforming them into structurally fortified agents with enhanced bioavailability.Keywords
This publication has 35 references indexed in Scilit:
- Structural and biological mimicry of protein surface recognition by α/β-peptide foldamersProceedings of the National Academy of Sciences of the United States of America, 2009
- All-Atom Model for Stabilization of α-Helical Structure in Peptides by Hydrocarbon StaplesJournal of the American Chemical Society, 2009
- SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to EnfuvirtideAntimicrobial Agents and Chemotherapy, 2009
- Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20*Online Journal of Public Health Informatics, 2009
- Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsProceedings of the National Academy of Sciences of the United States of America, 2008
- Potent D-peptide inhibitors of HIV-1 entryProceedings of the National Academy of Sciences of the United States of America, 2007
- Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virusProceedings of the National Academy of Sciences of the United States of America, 2007
- Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D- and L-cysteine at positions i and i+3, respectively, derived from HIV-1 gp41 C-peptideExperimental & Molecular Medicine, 2006
- The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected AdultsAIDS Research and Human Retroviruses, 2002
- Structure of influenza haemagglutinin at the pH of membrane fusionNature, 1994